Jalid Sehouli
#131,209
Most Influential Person Now
Researcher
Jalid Sehouli's AcademicInfluence.com Rankings
Jalid Sehouliphilosophy Degrees
Philosophy
#6377
World Rank
#9407
Historical Rank
Logic
#3553
World Rank
#4735
Historical Rank
Download Badge
Philosophy
Why Is Jalid Sehouli Influential?
(Suggest an Edit or Addition)Jalid Sehouli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A phase 3 trial of bevacizumab in ovarian cancer. (2011) (1534)
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. (2019) (829)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (2020) (559)
- Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. (2010) (509)
- OVARIAN CANCER (2016) (439)
- Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial (2006) (374)
- Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. (2006) (363)
- Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. (2007) (322)
- The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids (2015) (305)
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms (2019) (287)
- Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. (2001) (285)
- Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. (2009) (272)
- Magnetic nanoparticles for interstitial thermotherapy – feasibility, tolerance and achieved temperatures (2006) (256)
- Contemporary management of endometrial cancer (2012) (250)
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. (2012) (242)
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. (2019) (241)
- Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO (2010) (232)
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer (2008) (218)
- Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma (2015) (211)
- Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential (2005) (207)
- ErbB-3 predicts survival in ovarian cancer. (2006) (199)
- Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer (2008) (195)
- Clinical Trials in Recurrent Ovarian Cancer (2011) (177)
- The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications (2016) (172)
- Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression (2004) (171)
- Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study (2015) (169)
- An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. (2010) (165)
- Emergency ultrasound-based algorithms for diagnosing blunt abdominal trauma. (2005) (157)
- Randomized controlled phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – AGO DESKTOP III/ENGOT ov20 (2017) (151)
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. (2019) (150)
- Balanced crystalloid compared with balanced colloid solution using a goal-directed haemodynamic algorithm. (2013) (147)
- The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study (2018) (134)
- Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. (2008) (134)
- Systematic review and meta‐analysis of emergency ultrasonography for blunt abdominal trauma (2001) (132)
- Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes—A Meta-Analysis (2016) (130)
- Intra‐abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer (2009) (122)
- Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. (2004) (120)
- Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer (2009) (120)
- Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. (2013) (119)
- Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. (2008) (118)
- Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells (2005) (116)
- Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer (2003) (113)
- Safety and dose modification for patients receiving niraparib (2018) (111)
- GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis (2018) (110)
- Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) (2021) (109)
- Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. (2010) (109)
- Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. (2017) (106)
- Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients (2010) (106)
- The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. (2013) (105)
- Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. (2013) (105)
- A prognostic gene expression index in ovarian cancer—validation across different independent data sets (2009) (104)
- Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort (2011) (101)
- Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis (2012) (101)
- Prognostic significance of Dicer expression in ovarian cancer—link to global microRNA changes and oestrogen receptor expression (2009) (96)
- Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data (2012) (94)
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. (2016) (94)
- Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study (2021) (93)
- Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1) (2017) (93)
- Topotecan Chemotherapy in Patients with Breast Cancer and Brain Metastases: Results of a Pilot Study (2001) (92)
- Original Paper: A likelihood ratio approach to meta-analysis of diagnostic studies (2003) (91)
- Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. (2006) (89)
- Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20 (2020) (89)
- LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. (2017) (88)
- Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). (2007) (88)
- Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. (2011) (87)
- Epigenetic quantification of tumor-infiltrating T-lymphocytes (2011) (85)
- Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. (2008) (82)
- Liver resection for metastases from breast cancer (2008) (81)
- Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study (2008) (81)
- BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). (2014) (80)
- A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. (2013) (79)
- A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection (2011) (79)
- Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. (2020) (75)
- Functional and anatomic results of amnion vaginoplasty in young women with Mayer-Rokitansky-Küster-Hauser syndrome. (2010) (74)
- Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients (2010) (73)
- Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. (2021) (72)
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. (2012) (72)
- Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis (2010) (72)
- Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. (2013) (71)
- Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients (2005) (70)
- Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study (2015) (70)
- Long‐term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies (2010) (68)
- The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. (2006) (66)
- Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. (2018) (66)
- TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7) (2019) (66)
- Delaying surgery for patients with a previous SARS-CoV-2 infection (2020) (66)
- Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. (2010) (65)
- Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers (2011) (65)
- Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. (2016) (65)
- Expression of IL-10 in patients with ovarian carcinoma. (2006) (65)
- Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation (2019) (65)
- Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2018) (63)
- Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation (2013) (63)
- Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. (2013) (63)
- Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. (2016) (63)
- Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. (2011) (62)
- Operative Results after Primary and Secondary Debulking‐Operations in Advanced Ovarian Cancer (AOC) (1998) (61)
- Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer (2016) (61)
- Perspectives, fears and expectations of patients with gynaecological cancers during the COVID‐19 pandemic: A Pan‐European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) (2020) (61)
- Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. (2014) (60)
- Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review (2019) (60)
- Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential. (2013) (60)
- Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium (2012) (59)
- Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium (2013) (57)
- Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. (2008) (56)
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. (2018) (55)
- Current and future options in the treatment of malignant ascites in ovarian cancer. (2009) (54)
- Methylation status of TUSC3 is a prognostic factor in ovarian cancer (2013) (53)
- ABC transporter gene expression in benign and malignant ovarian tissue. (2010) (53)
- Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. (2007) (53)
- Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. (2016) (52)
- Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment (2020) (52)
- The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. (2009) (51)
- TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7). (2017) (51)
- The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial (2006) (51)
- A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. (2009) (50)
- Patient Empowerment Improved Perioperative Quality of Care in Cancer Patients Aged ≥ 65 Years – A Randomized Controlled Trial (2015) (50)
- The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. (2007) (49)
- Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. (2016) (49)
- Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium—OVCAD (2012) (48)
- Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. (2007) (48)
- Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer (2006) (48)
- BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment. (2010) (48)
- Characterization of endometriosis-associated immune cell infiltrates (EMaICI) (2016) (47)
- Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. (2010) (47)
- Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study (2014) (47)
- Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic (2020) (46)
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum (2020) (46)
- Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. (2019) (46)
- MALDI‐Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods (2018) (45)
- High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism (2017) (44)
- Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium (2012) (44)
- Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study (2020) (44)
- Polymorphism of IL-1 receptor antagonist gene: role in cancer. (2002) (44)
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. (2011) (43)
- Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (2011) (43)
- ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma (2021) (43)
- Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer (2011) (42)
- Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration (2016) (41)
- Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. (2010) (41)
- Systematic Evaluation of the Intraoperative Tumor Pattern in Patients With Borderline Tumor of the Ovary (2009) (41)
- Brain metastases from epithelial ovarian cancer: overview and optimal management. (2009) (40)
- Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany (2007) (40)
- Association of myeloperoxidase with ovarian cancer (2013) (40)
- Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial. (2014) (40)
- Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. (2013) (40)
- Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. (2015) (39)
- Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. (2014) (39)
- Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. (2018) (39)
- Clinical Outcome of Tertiary Surgical Cytoreduction in Patients with Recurrent Epithelial Ovarian Cancer (2010) (39)
- Image-guided volumetric modulated arc therapy for breast cancer: a feasibility study and plan comparison with three-dimensional conformal and intensity-modulated radiotherapy. (2013) (39)
- Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium (2013) (39)
- Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study (2015) (39)
- Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer (2011) (39)
- HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? (2018) (38)
- Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status. (2010) (38)
- Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. (2003) (37)
- Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO (2015) (37)
- Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. (2017) (36)
- Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium (2017) (36)
- Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. (2003) (36)
- Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer (2018) (36)
- Checkpoint-inhibition in ovarian cancer: rising star or just a dream? (2018) (36)
- Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. (2016) (36)
- Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. (2009) (36)
- The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study (2013) (35)
- Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study (2010) (35)
- A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. (2002) (35)
- Myofibroblasts Are Evidence of Chronic Tissue Microtrauma at the Endometrial–Myometrial Junctional Zone in Uteri With Adenomyosis (2017) (35)
- Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al (2017) (35)
- An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. (2006) (35)
- Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5). (2014) (34)
- Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. (2009) (34)
- Surgical and systemic management of endometrial cancer: an international survey (2015) (34)
- Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors (2014) (34)
- Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer (2015) (34)
- Impact of Obesity on Operative Morbidity and Clinical Outcome in Primary Epithelial Ovarian Cancer after Optimal Primary Tumor Debulking (2011) (34)
- Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer (2007) (33)
- Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation. (2019) (33)
- Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients. (2012) (33)
- Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients (2007) (33)
- Long-term effects of neovaginal reconstruction with sigmoid loop technique on sexual function and self image in patients with gynecologic malignancies: results of a prospective study. (2008) (33)
- An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas (2011) (33)
- Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer (2017) (32)
- First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. (2002) (32)
- A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium (2013) (32)
- Identification of 34 N-glycan isomers in human serum by capillary electrophoresis coupled with laser-induced fluorescence allows improving glycan biomarker discovery (2014) (32)
- Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: Evaluation of two annular-phased-array applicators (2008) (32)
- Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high‐risk histopathological features, and lethal recurrence rates (2016) (32)
- Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO (2007) (32)
- A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. (2012) (32)
- Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. (2006) (32)
- Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high‐grade serous ovarian cancer (2016) (32)
- Vulvar cancer in Germany: increase in incidence and change in tumour biological characteristics from 1974 to 2013 (2017) (31)
- European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies (2010) (31)
- Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer (2012) (31)
- Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis (2009) (31)
- Expression of multidrug resistance‐associated protein 1 in invasive ovarian carcinoma: implication for prognosis (2009) (31)
- Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and Treatment (2013) (31)
- Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. (2008) (30)
- Polymorphism of the IL-8 gene and the risk of ovarian cancer. (2015) (30)
- The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. (2016) (30)
- LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) (2020) (30)
- Primary Radical Surgery in Elderly Patients With Epithelial Ovarian Cancer: Analysis of Surgical Outcome and Long-Term Survival (2009) (30)
- Atypical Protein Kinase C ζ Exhibits a Proapoptotic Function in Ovarian Cancer (2010) (30)
- Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. (2016) (30)
- European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic (2020) (30)
- Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study (2016) (29)
- Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. (2011) (29)
- Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer. (2010) (29)
- Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. (2017) (29)
- Alterations in Expression Pattern of Splicing Factors in Epithelial Ovarian Cancer and its Clinical Impact (2013) (29)
- Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. (2012) (29)
- Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer (2014) (29)
- Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. (2006) (29)
- A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer. (2006) (29)
- Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma (2015) (29)
- Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. (2003) (29)
- The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study (2016) (28)
- The genetic landscape of 87 ovarian germ cell tumors. (2018) (28)
- Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology. A NOGGO-AGO* survey of 144 Gynecological Departments in Germany. (2016) (28)
- An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma (2007) (28)
- A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. (2019) (28)
- Current and future options in the management and treatment of uterine sarcoma (2014) (27)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. (2021) (27)
- A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer (2017) (27)
- Acute‐phase glycoprotein N‐glycome of ovarian cancer patients analyzed by CE‐LIF (2016) (27)
- High-frequency breast ultrasound for the detection of microcalcifications and associated masses in BI-RADS 4a patients. (2011) (27)
- The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases (2014) (26)
- BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. (2020) (26)
- Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? (2013) (26)
- LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial (2020) (26)
- Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. (2009) (26)
- Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer (2019) (26)
- Prognostic significance of angiogenic factors in uterine cervical cancer. (2011) (26)
- Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. (2011) (26)
- Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option? (2012) (26)
- Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTO (2016) (26)
- Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy (2015) (26)
- Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial. (2020) (25)
- Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer (2017) (25)
- The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis (2018) (25)
- Discriminatory power of 3.5 MHz convex and 7.5 MHz linear ultrasound probes for the imaging of traumatic splenic lesions: a feasibility study. (2001) (25)
- A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants. (2015) (25)
- European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery (2021) (25)
- Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis (2005) (25)
- Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer (2015) (25)
- Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer (2019) (25)
- Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. (2014) (24)
- Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. (2009) (24)
- HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. (2018) (24)
- Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany (2009) (24)
- Transthyretin, a biomarker for nutritional status and ovarian cancer. (2005) (24)
- Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. (2020) (24)
- Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis (2012) (24)
- IMP3 Expression in Human Ovarian Cancer is Associated With Improved Survival (2009) (24)
- HE4 Expression in Plasma Correlates with Surgical Outcome and Overall Survival in Patients with First Ovarian Cancer Relapse (2014) (24)
- Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study (2009) (23)
- Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer1 (2018) (23)
- ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer. (2014) (23)
- The ascites N-glycome of epithelial ovarian cancer patients. (2017) (23)
- Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer. (2011) (23)
- Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer. (2003) (23)
- Evaluation of a hormone receptor‐positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin‐fixed paraffin‐embedded tissue (2011) (22)
- Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases. (2012) (22)
- SPOC1, a novel PHD‐finger protein: Association with residual disease and survival in ovarian cancer (2005) (22)
- Efficient Prevention Strategy against the Development of a Palmar-Plantar Erythrodysesthesia during Chemotherapy (2013) (22)
- Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium (2014) (22)
- Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma (2012) (22)
- Symptomization and triggering processes: ovarian cancer patients' narratives on pre-diagnostic sensation experiences and the initiation of healthcare seeking. (2014) (22)
- Laparoscopic radical hysterectomy in cervical cancer as total mesometrial resection (L-TMMR): a multicentric experience. (2015) (22)
- Guidelines for Vulvar and Vaginal Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. (2020) (21)
- Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer. (2013) (21)
- A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). (2013) (21)
- A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. (2012) (21)
- Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma: Prognostic Impact and Link to NF-&kgr;B Pathway (2014) (20)
- Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. (2006) (20)
- Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network. (2016) (20)
- Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. (2012) (20)
- Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. (2009) (20)
- Incidence Patterns and Survival of Gynecological Sarcoma in Germany: Analysis of Population-Based Cancer Registry Data on 1066 Women (2017) (20)
- Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network (2016) (20)
- Expression and localization of e-cadherin in epithelial ovarian cancer. (2010) (20)
- LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2020) (20)
- HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium (2014) (19)
- Laparoscopic Neuronavigation for Deep Lateral Pelvic Endometriosis: Clinical and Surgical Implications. (2018) (19)
- A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: An evidence-based proposal for patient selection. (2011) (19)
- Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report. (2006) (19)
- PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. (2015) (19)
- Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13) (2013) (19)
- The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns (2013) (19)
- Salvage Surgery Due To Bowel Obstruction in Advanced or Relapsed Ovarian Cancer Resulting in Short Bowel Syndrome and Long-Life Total Parenteral Nutrition: Surgical and Clinical Outcome (2013) (19)
- Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. (2019) (18)
- Surgery in recurrent ovarian cancer (2019) (18)
- The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. (2018) (18)
- Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium. (2013) (18)
- Current role and future aspects of topotecan in relapsed ovarian cancer (2009) (18)
- Sialic acid methylation refines capillary electrophoresis laser‐induced fluorescence analyses of immunoglobulin G N‐glycans of ovarian cancer patients (2014) (18)
- Controversies in the management of ovarian cancer--pros and cons for lymph node dissection in ovarian cancer. (2009) (18)
- Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. (2020) (18)
- Treatment decision-making processes in the systemic treatment of ovarian cancer: review of the scientific evidence. (2012) (18)
- OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. (2019) (18)
- Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). (2018) (18)
- Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. (2012) (18)
- ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. (2014) (17)
- Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients (2007) (17)
- Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue (2009) (17)
- Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients. (2007) (17)
- A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO) (2016) (17)
- Nerve-sparing radical hysterectomy: steps to standardize surgical technique (2019) (17)
- Accumulation of Selected Carotenoids, α-Tocopherol and Retinol in Human Ovarian Carcinoma Ascitic Fluid (2004) (17)
- Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. (2019) (17)
- Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab (2015) (17)
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015 (2015) (16)
- Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology (2020) (16)
- Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. (2019) (16)
- Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study (2017) (16)
- Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging (2018) (16)
- AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer (2016) (16)
- Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer (2013) (16)
- Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. (2013) (16)
- Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. (2010) (16)
- Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA (2018) (16)
- Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). (2009) (16)
- Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. (2006) (15)
- The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer. (2006) (15)
- Epithelial Ovarian Cancer: Focus on Targeted Therapy (2011) (15)
- AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer. (2015) (15)
- The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study. (2017) (15)
- Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study (2008) (15)
- Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy (2022) (15)
- Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer (2019) (15)
- Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study (2014) (15)
- Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. (2022) (15)
- New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. (2008) (15)
- A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer (2010) (14)
- Risk Factors of Lymph Nodes Metastases by Endometrial Cancer: A Retrospective One-center Study. (2016) (14)
- Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. (2008) (14)
- Review of gemcitabine‐based combinations for platinum‐resistant ovarian cancer (2005) (14)
- A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis (2012) (14)
- Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer (2018) (14)
- Effects of sarcopenia and malnutrition on morbidity and mortality in gynecologic cancer surgery: results of a prospective study (2021) (14)
- Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery (2018) (14)
- CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience. (2011) (14)
- Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology (2016) (14)
- A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer (2019) (14)
- First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report (2012) (14)
- Current management of ovarian cancer. (2015) (13)
- Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study. (2019) (13)
- The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German “Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)”, the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology (2018) (13)
- Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium (2014) (13)
- Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. (2021) (13)
- Surgery for recurrent ovarian cancer: Options and limits. (2017) (13)
- Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism (2018) (13)
- Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer (2012) (13)
- Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells (2016) (13)
- Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium (2019) (13)
- Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology) (2013) (13)
- Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients. (2013) (13)
- Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum (2004) (13)
- Current role and future aspects of topotecan in relapsed ovarian cancer. (2009) (12)
- Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients. (2015) (12)
- Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study. (2021) (12)
- Investigation of doxorubicin on the skin: A spectroscopic study to understand the pathogenesis of PPE (2005) (12)
- Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group. (2011) (12)
- Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study (2022) (12)
- What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer. (2009) (12)
- A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. (2012) (12)
- Neuroendocrine Neoplasms of the Ovary: A Retrospective Study of the North Eastern German Society of Gynecologic Oncology (NOGGO). (2016) (12)
- Morphology and tumour‐infiltrating lymphocytes in high‐stage, high‐grade serous ovarian carcinoma correlated with long‐term survival (2018) (12)
- Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial (2017) (12)
- Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium. (2018) (12)
- First evaluation of the diagnostic accuracy of an automated 3D ultrasound system in a breast screening setting. (2011) (12)
- Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors. (2015) (12)
- An estrogen receptor α-dependent regulation of estrogen receptor–related receptor α in the proliferation of endometrial carcinoma cells (2006) (12)
- Regional hyperthermia of the abdomen, a pilot study towards the treatment of peritoneal carcinomatosis (2015) (12)
- The -463G/A polymorphism in myeloperoxidase gene and cervical cancer. (2007) (11)
- Mesothelin as a target for cervical cancer therapy (2018) (11)
- A new therapeutical approach: Topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first‐line chemotherapy with paclitaxel and platinum (2003) (11)
- Application of an ointment with high radical protection factor as a prevention strategy against PPE. (2012) (11)
- Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients (2017) (11)
- Elderly ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). (2016) (11)
- Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology. (2012) (11)
- Evidence-based perioperative management: strategic shifts in times of fast track surgery. (2009) (11)
- RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers (2020) (11)
- Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO) (2007) (11)
- Value of preoperative transvaginal sonography (TVS) in the description of tumor pattern in ovarian cancer patients: results of a prospective study. (2007) (11)
- Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer. (2018) (11)
- Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study). (2018) (11)
- [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany]. (2010) (11)
- The growth of uterine myomas in untreated women: influence factors and ultrasound monitoring (2017) (11)
- Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery∗ (2015) (11)
- Preoperative transvaginal ultrasound (TVS) in the description of pelvic tumor spread in endometrial cancer: results of a prospective study. (2008) (11)
- PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives (2016) (10)
- Endo-β-N-acetylglucosaminidase H de-N-glycosylation in a domestic microwave oven: application to biomarker discovery. (2013) (10)
- Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study (2014) (10)
- Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. (2007) (10)
- Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC). (2016) (10)
- Long term combination treatment with bevacizumab, pegylated liposomal doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: a case report and review of the literature. (2011) (10)
- Why Institutions Do not Participate in Ovarian Cancer Trials – Results from a Survey in Germany (2004) (10)
- Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology. (2010) (10)
- Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer (2019) (10)
- Lipid reprogramming induced by the TFEB-ERRα axis enhanced membrane fluidity to promote EC progression (2021) (10)
- Independent association between leptin and blood pressure during third trimester in normal and gestational diabetic pregnancies. (2005) (10)
- Incidence and Pattern of Spread of Lymph Node Metastasis in Patients With Low-grade Serous Ovarian Cancer (2019) (10)
- Total retroperitoneal en bloc resection of multivisceral-peritoneal packet (TROMP operation): a novel surgical technique for advanced ovarian cancer (2020) (10)
- The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study (2015) (10)
- Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance (2020) (10)
- Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer (2020) (10)
- Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging (2020) (10)
- Arrangement of myofibroblastic and smooth muscle-like cells in superficial peritoneal endometriosis and a possible role of transforming growth factor beta 1 (TGFβ1) in myofibroblastic metaplasia (2018) (10)
- miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. (2020) (10)
- Impact of Ascites on the Perioperative Course of Patients With Advanced Ovarian Cancer Undergoing Extensive Cytoreduction: Results of a Study on 119 Patients (2014) (10)
- Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group. (2011) (10)
- LBA41A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma (2017) (10)
- Ovarian cancer—can intraperitoneal therapy be regarded as new standard in Germany? (2006) (10)
- Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients (2018) (10)
- When and how should peritoneal endometriosis be operated on in order to improve fertility rates and symptoms? The experience and outcomes of nearly 100 cases (2021) (10)
- The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). (2015) (10)
- The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer (2018) (9)
- Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34) (2020) (9)
- Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial) (2020) (9)
- Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study. (2015) (9)
- A Concise Paradigm on Radical Hysterectomy: The Comprehensive Anatomy of Parametrium, Paracolpium and the Pelvic Autonomic Nerve System and Its Surgical Implication (2020) (9)
- Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study (2009) (9)
- Palmoplantar Erythrodysesthesia-Like Skin Symptoms in Patients under Various Chemotherapeutics: Preventive and Therapeutic Options (2014) (9)
- Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging (2021) (9)
- ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer. (2019) (9)
- Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study (2020) (9)
- Influence of Chemotherapy on the Antioxidant Status of Human Skin. (2016) (9)
- HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network. (2013) (9)
- Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy (2015) (9)
- Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer (2016) (9)
- Key regulator of cellular metabolism, estrogen-related receptor α, a new therapeutic target in endocrine-related gynecological tumor (2018) (9)
- Determination of Tumor-infiltrating CD8+ Lymphocytes in Human Ovarian Cancer (2013) (9)
- Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV) (2020) (9)
- EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM (2019) (9)
- Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer. (2017) (9)
- Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7) (2016) (9)
- Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial (2017) (9)
- Impact of brief prewarming on anesthesia-related core-temperature drop, hemodynamics, microperfusion and postoperative ventilation in cytoreductive surgery of ovarian cancer: a randomized trial (2019) (8)
- Influence of Mechanical Stress on Palmoplantar Erythrodysesthesia - a Case Report (2015) (8)
- Transfusion of red blood cells does not impact progression‐free and overall survival after surgery for ovarian cancer (2019) (8)
- Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells (2020) (8)
- Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR) (2005) (8)
- Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience (2018) (8)
- Sexually assaulted women: Results of a retrospective analysis of 850 women in Germany. (2020) (8)
- APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. (2019) (8)
- 24 UTERUS-11 STUDY: A randomized clinical trial on surgical staging versus ct-staging prior to primary chemoradiation in patients with FIGO2009 stages IIB-IVA cervical cancer (2019) (8)
- Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells (2018) (8)
- Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study (2018) (8)
- The involvement of retroperitoneal lymph nodes in primary serous-papillary peritoneal carcinoma. a systematic review of the literature. (2011) (8)
- Postoperative therapy modalities for cervical carcinoma. (2006) (8)
- Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. (2014) (8)
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. (2012) (8)
- miR‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients (2020) (8)
- Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study (2014) (8)
- Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. (2019) (8)
- Shed L-selectin (sCD62L) load in trauma patients. (2001) (8)
- The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer. (2011) (8)
- Is there a role for HIPEC in ovarian cancer? (2018) (8)
- [Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]. (2008) (7)
- The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium (2021) (7)
- Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al. (2017) (7)
- Abdominal Wall Endometriosis: Myofibroblasts as a Possible Evidence of Metaplasia: A Case Report (2016) (7)
- Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer (2020) (7)
- ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN—trial) (2021) (7)
- Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. (2009) (7)
- Unmet family planning needs among female refugees and asylum seekers in Germany – is free access to family planning services enough? Results of a cross-sectional study (2020) (7)
- [Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany]. (2003) (7)
- Dilution of Molecular–Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer (2019) (7)
- Clostridium septicum can cause distant myonecrosis in patients with ovarian cancer. (2013) (7)
- [Role of estrogen receptor-related receptors alpha, beta and gamma in ovarian cancer cells]. (2005) (7)
- Participation of elderly gynecological cancer patients in clinical trials (2018) (7)
- Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO‐ENGOT trial: EXPRESSION III (2017) (7)
- Adequate Utilization of Emergency Services in Germany: Is There a Differential by Migration Background? (2021) (7)
- Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis (2021) (7)
- New associate Editor Prof. Dr. J. Sehouli for the section Gynecologic Oncology (2016) (7)
- What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. (2017) (7)
- An estrogen receptor alpha-dependent regulation of estrogen receptor-related receptor alpha in the proliferation of endometrial carcinoma cells. (2006) (7)
- Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial. (2017) (6)
- Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer. (2004) (6)
- Surgery at primary versus relapsed epithelial ovarian cancer: a study on aspects of anaesthesiological management. (2015) (6)
- Are the Results of Randomized Trials Influenced by Preference Effects? Part I. Findings from a Systematic Review (2006) (6)
- Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma. (2017) (6)
- Possible role of the posterior compartment peritonectomy, as a part of the complex surgery, regarding recurrence rate, improvement of symptoms and fertility rate in patients with endometriosis, long term follow-up. (2020) (6)
- Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers (2017) (6)
- Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey (2019) (6)
- Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network (2017) (6)
- Can Fried Frailty Score predict postoperative morbidity and mortality in gynecologic cancer surgery? Results of a prospective study. (2020) (6)
- Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC (2005) (6)
- Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). (2012) (6)
- Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS). (2013) (6)
- Oncological outcome of surgical management in patients with recurrent uterine cancer—a multicenter retrospective cohort study—CEEGOG EX01 Trial (2019) (6)
- 594 Impact of the covid pandemic on gynaecological cancer surgery – results from the covidsurg gynaecological cancer international study (2020) (6)
- [Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO]. (2006) (6)
- Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer (2018) (6)
- Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given? (2020) (6)
- Interleukin-1 receptor antagonist gene polymorphism and cancer. (2002) (6)
- Prognostic significance of epithelial cells in the blood of patients with gynaecological malignancies. (2003) (6)
- A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial. (2014) (6)
- Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium (2019) (6)
- Pilot Study of Hydrolytically Activated Paclitaxel Prodrug Therapy in Patients with Progressive Malignancies (2002) (6)
- Clinical management of borderline tumours of the ovary - experience from the "Berlin online tumour conference for gynaecological malignancies". (2010) (5)
- Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study. (2010) (5)
- Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC) (2016) (5)
- Is endometrial cancer really a neurophobic tumor? A case report and review of the literature. (2014) (5)
- In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer. (2011) (5)
- Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary (2013) (5)
- Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). (2010) (5)
- Functional changes of immune cells: signal of immune tolerance of the ectopic lesions in endometriosis? (2021) (5)
- [NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]. (2007) (5)
- Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score (2021) (5)
- Self-Reported Long-Term Autonomic Function After Laparoscopic Total Mesometrial Resection for Early-Stage Cervical Cancer: A Multicentric Study (2017) (5)
- Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy – a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6) (2004) (5)
- Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death (2022) (5)
- Amelanotic metastasis of melanoma mimicking ovarian cancer: a case report and review of the literature. (2008) (5)
- Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer (2004) (5)
- Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle (2021) (5)
- Reconstructive surgical management of cryptomenorrhea because of complex uterovaginal malformations with duplicate uterus and complete vaginal agenesis. (2010) (5)
- Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study. (2021) (5)
- Surgical outcome and survival analysis of young patients with primary epithelial ovarian cancer. (2009) (5)
- Pleomorphic Rhabdomyosarcoma of the Uterus - Case Report and a Systematic Review of the Literature. (2017) (5)
- Perspectives, Fears and Expectations of Patients with Gynaecological Cancers During the COVID-19 Pandemic: A Pan-European Study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) (2020) (5)
- ERRα inhibitor acts as a potential agonist of PPARγ to induce cell apoptosis and inhibit cell proliferation in endometrial cancer (2020) (5)
- Diagnostic value of plasma NGAL and intraoperative diuresis for AKI after major gynecological surgery in patients treated within an intraoperative goal-directed hemodynamic algorithm (2017) (5)
- Perspectives of immunotherapy in metastatic breast cancer. (2005) (5)
- Results of a German wide survey towards current surgical approach in early stage cervical cancer NOGGO MONITOR 11 (2021) (5)
- LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial (2020) (5)
- Biological Impact of Unilateral Oophorectomy: Does the Number of Ovaries Really Matter? (2020) (5)
- First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer. (2011) (5)
- [Fat-saturated, contrast-enhanced spin-echo sequences in the magnetic resonance tomographic diagnosis of peritoneal carcinosis]. (1999) (5)
- Erratum to: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications (2016) (5)
- Anxiety of myoma patients: results of standardized interviews with the State Trait Anxiety Inventory and the Kessler 10 questionnaire (2020) (5)
- A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy. (2012) (5)
- Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report (2019) (5)
- Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study (2021) (5)
- Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer. (2004) (5)
- Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis (2021) (4)
- Peritoneal and upper genital tract tuberculosis. (2020) (4)
- Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial (2022) (4)
- New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples (2017) (4)
- Predictive factors in relapsed ovarian cancer for complete tumor resection. (2011) (4)
- Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines—A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters (2021) (4)
- Neurogenic Inflammation in the Context of Endometriosis—What Do We Know? (2021) (4)
- Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring (2021) (4)
- Post-operative management and follow-up of surgical treatment in the case of rectovaginal and retrocervical endometriosis (2020) (4)
- Adjuvant sequential chemo-radiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO. (2011) (4)
- Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS. (2016) (4)
- MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer. (2011) (4)
- Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study (2010) (4)
- Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group (2020) (4)
- [Adjuvant chemotherapy of cervix carcinoma--results of a phase II study]. (2001) (4)
- Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test) (2017) (4)
- Pros and cons for systemic therapy in recurrent ovarian cancer. (2009) (4)
- 378 Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany (2010) (4)
- Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer (2019) (4)
- The impact of preoperative malnutrition on surgery outcome and overall survival in ovarian or peritoneal cancer patients: A prospective study. (2016) (4)
- Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study (2020) (4)
- Survey among German gynecologists on the clinical management of patients with sarcomas of the uterus. (2013) (4)
- LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study. (2018) (4)
- Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup Study. (2010) (4)
- Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey (2020) (4)
- Sexual, bladder and bowel function following different minimally invasive techniques of radical hysterectomy in patients with early-stage cervical cancer (2021) (4)
- In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging (2022) (4)
- The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. (2015) (4)
- Expression III: What do primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a survey in eight European countries with 1,743 patients (NOGGO/ENGOT-OV9 study). (2013) (4)
- Taking Responsibility: Ovarian Cancer Patients’ Perspectives on Delayed Healthcare Seeking (2017) (4)
- Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies. (2015) (4)
- Detection of epithelial carcinoma cells in the blood of patients with gynaecological malignancies. (2003) (4)
- Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883) (2020) (4)
- Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study. (2012) (4)
- Pain Mechanisms in Peritoneal Diseases Might Be Partially Regulated by Estrogen (2018) (4)
- Title Page / Contents / Guidelines for Authors / Imprint (2015) (3)
- What are the individual perceptions of patients with borderline tumours of the ovary in regard to pathogenesis and prognosis? A structured survey on 60 women (2010) (3)
- Endometriosis-associated Pain in Patients with and without Hormone Therapy (2017) (3)
- 956PInfluence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC) (2017) (3)
- Secondary malignancies in long-term ovarian cancer survivors: results of the ‘Carolin meets HANNA’ study (2021) (3)
- Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer (2018) (3)
- Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study (2021) (3)
- The influence of obesity on tumor recurrence in vulvar cancer patients. (2019) (3)
- Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey (2022) (3)
- Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment (2020) (3)
- Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC). (2022) (3)
- Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. (2021) (3)
- 8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials (2011) (3)
- Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry (2022) (3)
- Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial. (2017) (3)
- A case of primary peritoneal carcinoma: evidence for a precursor in the fallopian tube. (2014) (3)
- Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer (2020) (3)
- Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium (2014) (3)
- Multivisceral surgery for advanced gynaecological malignancies (2003) (3)
- Quality of life and symptoms in longterm survivors with ovarian cancer: It's still an issue. Expression VI - Carolin meets HANNA - holistic analysis of long-term survival with ovarian cancer: The international NOGGO, ENGOT and GCIG survey. (2018) (3)
- What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients. (2010) (3)
- Current practice and physicians’ opinion about preoperative hair removal as a part of ERAS pathway implementation in gynecology and gynecology–oncology: a NOGGO-AGO survey of 148 gynecological departments in Germany (2019) (3)
- Phase I/II trial of the anti-idiotypic monoclonal antibody ACA125 in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer (2005) (3)
- 16th Biennial Meeting of the International Gynecologic Cancer Society (2016) (3)
- Management of malignant dysgerminoma of the ovary (2022) (3)
- 843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100 (2020) (3)
- A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer (2021) (3)
- Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee (2022) (3)
- Angiosarcomas of Primary Gynecologic Origin – A Case Series and Review of the Literature (2020) (3)
- Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin. (2008) (3)
- European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma (2021) (3)
- Dynamic muscle O2 saturation response is impaired during major non-cardiac surgery despite goal-directed haemodynamic therapy. (2016) (3)
- Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology. (2017) (3)
- Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO). (2009) (3)
- The Value of Serum CA 125 in the Diagnosis of Borderline Tumors of the Ovary (2015) (2)
- Reconstructive Surgery versus Primary Closure following Vulvar Cancer Excision: A Wide Single-Center Experience (2022) (2)
- Topotecan Weekly versus Topotecan Five-day Schedule in Patients with Platinum-resistant Ovarian Cancer — Which Is the Best Regimen? (2007) (2)
- Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. (2012) (2)
- Current management of borderline ovarian tumors: A multicenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO). (2009) (2)
- Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy - a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6). (2004) (2)
- The influence of chemotherapy induced nausea and vomiting (CINV) on survival: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1213 recurrent ovarian cancer patients. (2017) (2)
- 816MO AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST) (2020) (2)
- Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer (2020) (2)
- Nerve-Sparing Systematic Lymph Node Dissection in Gynaecological Oncology: An Innovative Neuro-Anatomical and Surgical Protocol for Enhanced Functional Outcomes (2020) (2)
- What do 676 primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a German survey of the northeastern German Society of Gynecological Oncology (NOGGO). (2012) (2)
- [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]. (2018) (2)
- Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer (2021) (2)
- Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer. (2020) (2)
- The impact of health related quality of life (HRQoL) on short term survival of recurrent ovarian cancer patients: Analysis of pooled data from the North-Eastern German Society of Gynecological Oncology (NOGGO) meta data base. (2018) (2)
- Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma (2017) (2)
- Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses of IMagyn050/GOG3015/ENGOT-ov39 (2021) (2)
- Development of a Questionnaire for Monitoring Risk Factors for Chemotherapy-induced Nausea and Vomiting – A NOGGO Pilot Study (2018) (2)
- Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study. (2009) (2)
- Relapsed ovarian cancer after failure of first-line chemotherapy with platin and paclitaxel — a phase II study (2001) (2)
- Use of paclitaxel for advanced ovarian cancer in clinical practice: analysis of 541 patients. Results from a German multi-centre observational study. (2010) (2)
- Prognostic Value and Therapeutic Implications of Pleural Carcinosis and Malignant Pleural Effusion in Advanced Epithelial Ovarian Cancer (2021) (2)
- Dynamic muscle O2 saturation response is impaired during major non-cardiac surgery despite goal-directed haemodynamic therapy (2016) (2)
- AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group. (2004) (2)
- 186 Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT (2021) (2)
- Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer. (2022) (2)
- Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma (2018) (2)
- Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC (2005) (2)
- Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study (2022) (2)
- ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. (2022) (2)
- The role of acculturation in migrants’ use of gynecologic emergency departments (2020) (2)
- Preservation of stemness in high-grade serous ovarian cancer organoids requires low Wnt environment (2019) (2)
- Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients (2016) (2)
- Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC). (2018) (2)
- Discussion: session 2. (2013) (2)
- SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer. (2021) (2)
- 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial (2022) (2)
- Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO). (2013) (2)
- Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium (2013) (2)
- Preoperative malnutrition as criteria for tumor resection completeness and overall survival in patients with ovarian cancer: Results of a prospective study. (2014) (2)
- Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism (2018) (2)
- Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group (2021) (2)
- Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planed 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR). (2010) (2)
- PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCER (2018) (2)
- Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review. (2017) (2)
- Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense? (2020) (2)
- Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study (2022) (2)
- Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HR-QoL) in Patients with Ovarian Cancer: What Is Different Compared to Healthy Women? (2021) (2)
- 2022-RA-1057-ESGO Outcomes of gynaecological cancer surgery during the covid-19 pandemic: results from the international, multicenter, prospective covidsurg-gynaecological cancer study (2022) (2)
- A rare case of ovarian cancer in pregnancy complicated by pulmonary embolus and myocardial infarction: management dilemmas (2014) (2)
- Feasibility and Safety of Laparoscopic Total Mesometrial Resection in Early-stage Cervical Cancer. (2016) (2)
- 2022-RA-1673-ESGO The digital trans-african E-health network- a clinical partnership experience (2022) (2)
- Results of the second interim analysis of C-PATROL: A non-interventional study on olaparib within German routine clinical practice (2019) (2)
- ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer (2019) (2)
- Discussion: session 1. (2013) (2)
- Evaluation of Biomarkers in Myoma Patients: A Prospective Study Investigating the Role of LDH, CA 125, and IGF-1 after Uterus-Preserving Surgical Therapy (2021) (2)
- Management von Borderlinetumoren des Ovars (BOT) (2005) (2)
- Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome (2022) (2)
- Effects of epigallocatechin gallate-enriched green tea extract capsules in uterine myomas: results of an observational study (2021) (2)
- Tumour biology in advanced ovarian cancer: Do older patients (>65 years) have other tumour characteristics than younger patients? (2004) (2)
- 199 Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer (2021) (2)
- Treatment of patients with chemotherapy-induced PPE using a prevention ointment containing high concentrations of antioxidants. (2012) (2)
- How frequently do female patients with gynecological cancers use unconventional cancer therapies? (2000) (2)
- 3D ultrasound as a surgical quality control of conization in patients with severe dysplasia: a prospective study (2020) (2)
- 1196 A randomised phase II study of combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. FANDANGO/ENGOT-EN1/FANDANGO (2021) (1)
- A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): Results of a NOGGO-AGO intergroup pi (2011) (1)
- What do adjuvant and metastatic breast cancer patients (BC) expect from their doctors? Final results of a german survey in 617 patients. (2006) (1)
- Investigation of cutaneous radical formation in patients receiving 5-fluorouracil, paclitaxel, docetaxel and capecitabine. (2016) (1)
- Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium (2012) (1)
- Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers (2018) (1)
- Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase III INNOVATE-3/ENGOT-ov50 study (2019) (1)
- 782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort (2021) (1)
- Endometriosis and Opioid Receptors: Are Opioids a Possible/Promising Treatment for Endometriosis? (2023) (1)
- Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study (2022) (1)
- Front Cover: MALDI‐Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods (2019) (1)
- Gynecologic oncology on the global health agenda: A wake-up call. (2021) (1)
- Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study (2012) (1)
- 241 Impact of co-medication on survival in patients with ovarian cancer – A analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators (2021) (1)
- Cell-free tumor DNA in peri-operative blood samples from advanced high-grade serous ovarian cancer patients with and without complete resection. (2017) (1)
- Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report. (2010) (1)
- Results of the CARMA study to investigate catumaxomab therapy for ascites related to peritoneal carcinomatosis in clinical practice. (2013) (1)
- P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study (2019) (1)
- Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts. (2018) (1)
- Prognostic factors for recurrence and survival in uncommon variants of vulvar cancer (2020) (1)
- Detection of free radical formation in human skin upon systemic application of chemotherapeutics. (2013) (1)
- Factors Influencing Postoperative Recovery and Time Off Work of Patients with Benign Indications for Surgery – Results of a Prospective Study (2020) (1)
- Gemcitabine In Recurrent Ovarian Cancer (2005) (1)
- A randomized phase II study of standard-versus high-dose pernetrexed in platinum-resistant epithellial ovarian cancer (2008) (1)
- Ki67 as a prognostic factor in low grade serous ovarian cancer (LGSOC): A retrospective analysis of the Tumor Bank Ovarian Cancer (TOC). (2017) (1)
- Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer (2022) (1)
- Laparoscopic radical hysterectomy and lymph node dissection learning experience at campus Virchow - Charite. (2013) (1)
- 2022-RA-672-ESGO Comparison of quality of life in patients with platinum-sensitive recurrent ovarian, fallopian tube and peritoneal cancer treated with trabectedin plus pegylated liposomal doxorubicin (PLD) or standard platinum-based therapy: Data look of the NOGGO S16/COMPASS trial (2022) (1)
- [Use of emergency rooms by so-called multiple users: results of a prospective study with special consideration of the migration status]. (2021) (1)
- 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (1)
- Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts). (2012) (1)
- Prognosis after local recurrence in vulvar cancer: A subset analysis of the AGO-CaRE-1 study. (2016) (1)
- The prognostic value of tumor residuals indicated by surgeon, by radiology or an integrated approach by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO Study led Intergroup trial AGO-OVAR 12. (2017) (1)
- 2022-RA-1644-ESGO The need for a unified appraoch in patient advocacy for global women´s health: a PARSGO initiative (2022) (1)
- Perioperative management of positioning in gynecological cancersurgery: a national NOGGO-AGO intergroup survey (2020) (1)
- 403 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-OV50/GOG-329/INNOVATE-3 (2020) (1)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer. (2016) (1)
- Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium (2022) (1)
- Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer. (2019) (1)
- Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT). (2013) (1)
- 2754 First interim analysis of OTILIA, a large German non-interventional study evaluating front-line bevacizumab (BEV)-containing therapy in patients with ovarian cancer (OC) (2015) (1)
- Epidermal growth factor receptor (EGFR) mutation rate in advanced ovarian cancer (AOC): Results of a prospective study in Caucasian patients (pts). (2006) (1)
- Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial. (2018) (1)
- P135 Discovery and validation of novel biomarkers for detection of epithelial ovarian cancer (2019) (1)
- MONITOR VII: Treatment strategies of low grade ovarian carcinomas - A German survey of the Charité - Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO. (2018) (1)
- TP004/#1457 Trial in progress of engot-CX8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer (2022) (1)
- Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC). (2015) (1)
- Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial (2022) (1)
- Treatment reality in elderly patients with advanced ovarian cancer: A prospective analysis of the OVCAD consortium. (2012) (1)
- Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC). (2010) (1)
- A phase I/II study of pemetrexed in combination with carboplatin in patients with platin sensitive recurrent ovarian or peritoneal cancer (PSOC) (2008) (1)
- Opportunistic Salpingectomy for the Primary Prevention of Ovarian Cancer. (2022) (1)
- [Benign symmetrical lipomatosis. A therapeutic dilemma?]. (1997) (1)
- Call for implementation research: cross-continental partnership experiences from the Trans-African Digital e-Health Network (i-STARC Project) (2023) (1)
- What is the evidence for lymphadenectomy in presumed early ovarian cancer? (2018) (1)
- Elucidating resistance mechanism to PARP inhibitors for the development of novel therapeutic approaches in high-grade serous ovarian cancer. (2020) (1)
- Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium (2021) (1)
- Vaginal fistula in a patient with relapsed ovarian cancer and amelanotic melanoma. (2012) (1)
- Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis (2012) (1)
- Silvernanoparticle‐induced hemolysis confounded with direct antiglobulin test‐negative autoimmune hemolytic anemias diagnosis (2022) (1)
- Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients (2021) (1)
- Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy. (2011) (1)
- Expression III: Final results of an international survey in eight European countries with 1,830 patients—What are the differences in expectations from their doctors and therapy management of patients with primary and recurrent ovarian cancer? (NOGGO/ENGOT-ov4 study). (2014) (1)
- A report on the Marrakech International Women’s Cancer Days: dialogs and implications (2018) (1)
- Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. (2022) (1)
- A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer. (2019) (1)
- Fatigue in long-term survivors with ovarian cancer: Results of Expression VI – Carolin meets HANNA – Holistic analysis of Long-term survival with ovarian cancer—The international NOGGO, ENGOT and GCIG survey. (2020) (1)
- A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium (2013) (1)
- 5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients (2007) (1)
- 416 Elucidating resistance mechanism to parp inhibitors for the development of novel therapeutic approaches in high-grade serous ovarian cancer (2020) (1)
- 958PImpact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO) (2017) (1)
- ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer (2020) (1)
- How is the clinical practice? Pegylated liposomal doxorubicin in the therapy of patients with recurrent ovarian cancer: Results of a German observational study (2008) (1)
- 758P Concordance between multiple HRD assays is substantial in high-grade ovarian cancer (2021) (1)
- 2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial (2022) (1)
- EUS-guided Transgastric Drainage to Manage a Postoperative Pancreatic Fistula After Distal Pancreatectomy and Splenectomy in Recurrent Ovarian Cancer: A Case Report (2021) (1)
- TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial (2019) (1)
- Toxicity of adjuvant sequential chemo- and radiotherapy of high-risk endometrial carcinoma (HREC)—Results of a phase II multicenter feasibility NOGGO study (2007) (1)
- 2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial (2022) (1)
- 181PVALIDATION OF MODELED EARLY LONGITUDINAL CA-125 KINETICS FOR PREDICTING SURVIVAL IN OVARIAN CANCER (OC) PHASE III TRIALS: COULD THE FAILURE OF ADDING GEMCITABINE TO CARBOPLATIN-PACLITAXEL (AGO-OVAR 9) HAVE BEEN FORESEEN EARLIER IN THE TRIAL? (2014) (1)
- Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma (2022) (1)
- Sinn und Unsinn der Schockraum-Sonografie beim stumpfen Bauchtrauma — Ergebnisse einer Bayes-Meta-Analyse/Sense and nonsense of emergency ultrasound for blunt abdominal trauma — a Bayesian meta-analysis (2001) (1)
- The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and survival in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1,213 patients. (2015) (1)
- HE4 is the marker of choice in discriminating endometriosis from ovarian cancer in pelvic mass patients: Sub-analysis of a prospective multicentric study (2018) (1)
- Dynamic of molecular subtypes of high‐grade serous ovarian cancer in paired primary and relapsed biopsies. (2019) (1)
- Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data. (2012) (1)
- Measure of Ovarian Symptoms and Treatment (2018) (1)
- Autoantibodies (AA) against the EGF/EGFR and VEGFA/VEGFR1 as prognosticator in epithelial ovarian cancer (EOC) patients. (2014) (1)
- Role of multivisceral cytoreductive surgery in patients (pts) with recurrent ovarian cancer (ROC): Who will not benefit from radical tumor debulking? (2007) (1)
- NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients. (2020) (1)
- Catumaxomab: Pharmacodynamic and pharmacokinetic data from phase IIIb CASIMAS study in patients with malignant ascites. (2012) (1)
- Palbociclib versus placebo in combination with letrozole for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN3/PALEO trial. (2017) (1)
- 764P Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study (2021) (1)
- “Like one part of a puzzle” — individualized aromatherapy for women with gynecological cancers in aftercare: results from a qualitative-focused mixed-methods study (2022) (1)
- Intra- and post-operative catumaxomab in patients with epithelial ovarian cancer: Two-year efficacy results from a multicenter, single-arm, phase II study. (2011) (1)
- Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial. (2015) (1)
- Edi-3, a new independent prognostic factor in ovarian cancer (2007) (0)
- 2022-RA-1438-ESGO Safety of total paracentesis in patients with malignant ascites from ovarian cancer: Results from the prospective, randomised ATLANTIS-trial (2022) (0)
- TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66) (2022) (0)
- Imatinib as a possible therapy option for cervical carcinoma (2008) (0)
- Randomized Phase III second-line trial: Topotecan (TM) vs. Topotecan/Etoposide (TE), vs. Topotecan/Gemcitabine (TG) for patients (pts) with relapsed ovarian cancer (ROC) (2006) (0)
- Maintenance of Quality of Life in Patients with Malignant Ascites During Treatment with the Trifunctional Antibody Catumaxomab: Results from the Phase III B Casimas Trial (2012) (0)
- Transcranial direct current stimulation to reduce chronic pelvic pain in endometriosis: Phase II Randomized Controlled Clinical Trial. (2023) (0)
- 00014 A PHASE II STUDY OF THE AGO OVARIAN CANCER STUDY GROUP (AGO-OVAR 2.6): ZD1839 IN COMBINATION WITH TAMOXIFEN IN REFRACTORY OVARIAN CANCER (2005) (0)
- 2022-RA-1093-ESGO Validation of self-sampling use for a multiplexed biomarker assay for HPV and dysplasia detection (2022) (0)
- Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies (2021) (0)
- 2022-RA-1611-ESGO Checkpoint inhibition in ovarian cancer works – A case report of complete response to immune check-point inhibition in a platinum resistant primary ovarian cancer patient with Lynch Syndrome (2022) (0)
- Vulvar cancer in Germany: Increase of incidence and change of tumor-biological characteristics in the period 1974-2013. (2017) (0)
- The FNTB-609G>C polymorphism as a possible predictive factor for efficacy of lonafarnib-treatment? Exploratory analysis of a randomized phase II clinical trial in stage IIb-IV ovarian cancer, treated with first-line platinum-based chemotherapy with or without lonafarnib. (2014) (0)
- The Tumor Bank Ovarian Cancer- a multicentric project (2005) (0)
- 2776 Cancer testis antigen Cyclin A1 is broadly expressed in ovarian cancer and associated with prolonged time to progression after platinum-based chemotherapy (2015) (0)
- 278 Real-life data on gynecological sarcoma – therapeutic strategies for primary treatment – results of the german sarcoma registry REGSA (NOGGO RU1) (2021) (0)
- OC17.05: New sonographic and hysteroscopic combined classification for surgical repair of isthmoceles in an outpatient setting to ensure maximum safety in minimal invasive surgery (2017) (0)
- 2022-RA-937-ESGO Rucaparib MAintenance after bevacizumab maintenance following carboplatin based chemotherapy in primary ovarian cancer (2022) (0)
- 169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas (2021) (0)
- The impact of polypharmacy and comorbidities on surgical morbidity and mortality in patients with gynecological malignancies: Results of a prospective study in 237 patients. (2017) (0)
- 8010 P53 codon 72 polymorphism does influence cervical cancer development in a German population (2009) (0)
- P158 PREDICTION OF INTESTINAL TUMOR INVOLVEMENT BY PARAMETERS OF NUTRITIONAL STATUS IN PATIENTS WITH PRIMARY OR RECURRENT OVARIAN CANCER (2008) (0)
- Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer (2018) (0)
- The European Network of Gynecological Oncological Trial Groups (2012) (0)
- 2022-RA-296-ESGO Non-pharmacological, patient-related predictive model for the occurrence of CINV: prospective, multicentre study in Germany (NOGGO-EMRISK trial) (2022) (0)
- 2022-RA-1256-ESGO First experiences of implementing ‘enhanced recovery after surgery’ (ERAS) at two German ESGO centers of excellence – KORE-INNOVATION: the first prospective clinical trial to assess a perioperative pathway to reduce postoperative complications in ovarian cancer patients (2022) (0)
- LB052 PREOPERATIVE NUTRITIONAL STAGING TO PREDICT CANCER DISSEMINATION AND INTESTINAL TUMOR INVOLVEMENT IN OVARIAN CANCER (2010) (0)
- Resection margin and locoregional control in vulvar cancer: A subset analysis of the AGO CARE-1 multicenter study. (2014) (0)
- Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC): Real-world data in Germany (QS Ovar of the AGO Study Group). (2022) (0)
- Does alopecia predict response to chemotherapy and prognosis in patients with advanced ovarian cancer? A meta-analysis of prospective randomized phase III trials with 5,114 patients of the AGO meta data base. (2013) (0)
- Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer (2022) (0)
- 1141P Prediction of cancer genomic instability using MALDI-imaging (2021) (0)
- Role of the novel PAI-1 RNA Binding Protein in Epithelial Ovarian Cancer (2006) (0)
- Effect of tumor-infiltrating T-lymphocytes on the aggressiveness of epithelial ovarian tumors. (2012) (0)
- Transthyretin – Microheterogeneity of a nutritional marker in ovarian cancer research (2005) (0)
- Perinatal Data of Refugee Women from the Gynaecology Department of Charité University Hospital Berlin Compared with German Federal Analysis (2021) (0)
- Do patients with recurrent ovarian cancer benefit from relative tumor reduction? Results from a prospective study. (2009) (0)
- [Effects of hyperemesis gravidarum on the course of pregnancy and birth, with special attention to the risk factor of migration background]. (2020) (0)
- Role of HE4, CA125, and ultrasound in risk assessment in pelvic mass patients: Results from a prospective, multicentric study. (2015) (0)
- The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study (2018) (0)
- 2022-RA-687-ESGO ARTISTRY-7: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68) (2022) (0)
- Impact of the trifunctional antibody catumaxomab followed by systemic chemotherapy (CTX) on overall survival (OS): Results of a subgroup analysis in patients (pts) with relapsed ovarian cancer (OC) and malignant ascites (MA). (2013) (0)
- Gynecologic oncology (2008) (0)
- Evaluation of treatment patterns and prognosis in correlation with age in patients with vulvar cancer: A subset analysis of the AGO-CaRE-1 study. (2020) (0)
- 2022-RA-1116-ESGO Barriers in the cervical cancer screening program and how self-sampling for HPV-testing is experienced as a solution to them (2022) (0)
- 2022-RA-1287-ESGO Case report of a patient with relapsed ovarian cancer and therapy with all three approved PARP-inhibitors (2022) (0)
- Prospective identification of prognostic factors for patients with early failure of advanced ovarian cancer who undergo primary cytoreductive surgery followed by chemotherapy: The AGO-OVAR 19/FRAGILE study (NCT02828618). (2022) (0)
- Expression III (I): A Cross Cultural Analysis of Ovarian Cancer Patient’s Preferences and Expectations on Physician-Patient Communication and Clinical Management in India and Germany (2021) (0)
- Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients. (2010) (0)
- 901PTHE IMPACT OF PLATINUM-BASED ADJUVANT TREATMENT ON THE OUTCOME OF BORDERLINE OVARIAN TUMORS: A META-ANALYSIS. (2014) (0)
- Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer: Results from retrospective part of HELP-ER study NOGGO TR2/ENGOT OV47-TR. (2021) (0)
- [Role of PAI-1 in gynaecological malignancies]. (2005) (0)
- Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer (2019) (0)
- Prognostic and predictive values of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial (2016) (0)
- Deregulation of hydroxybutyric acid metabolism provides diagnostic and prognostic biomarkers in ovarian high-grade serous carcinomas (2016) (0)
- Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC Network). (2017) (0)
- 0003: Gemcitabine-Paclitaxel-Carboplatin (TCG) VS. Paclitaxel-Carboplatin (TC) in Ovarian Cancer (OC): A Randomized Phase III Gcig Study (AGOOVAR-9, GINECO-TCG, NSGO-OC-0102) (2006) (0)
- Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT database. (2023) (0)
- GEFINITIB IN COMBINATION WITH TAMOXIFEN IN PATIENTS WITH OVARIAN CANCER REFRACTORY TO PLATINUM-TAXANE BASED THERAPY – A PHASE II STUDY OF THE AGO OVAR (2004) (0)
- Results of a German survey among patients with gynecological malignancies during the COVID-19 pandemic. (2021) (0)
- 8067 Platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study (2009) (0)
- How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO). (2012) (0)
- Dilution of molecular-pathologic gene signatures (MPG) by parameter unrelated to tumor biology (UTB) may prevent prediction of the resection status after debulking surgery in patients with advanced ovarian cancer (2019) (0)
- 2022-RA-1089-ESGO Opportunistic salpingectomy (OS) for prevention of ovarian cancer has become a de facto standard in Germany (2022) (0)
- 439 Primary symptoms in women with different histopathological subtypes of gynaecological sarcoma – results of a prospective intergroup registry for gynaecological sarcoma (REGSA – NOGGO RU1) (2020) (0)
- Reply to M Lee (2014) (0)
- P1061 Safety analysis of oral and intravenous treosulfan in heavily pretreated elderly patients with recurrent ovarian cancer: A prospective multicenter study of the NOGGO (2009) (0)
- Prognostic Significance of the postoperative Tumorrest in Patients with epithelial Ovarian Carcinoma FIGO IIA-IV: Analysis of the OVCAD Data (2012) (0)
- [Ovarian cancer -- can peritoneal therapy be regarded as new standard?]. (2006) (0)
- 2022-RA-1564-ESGO Patients’ perspectives on changes in cancer care during the COVID-19 pandemic: Results of a German survey among patients with gynecological malignancies (2022) (0)
- P1-IS-41 Final results of a randomized multicenter phase III trial in 505 patients with relapsed ovarian cancer : topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine (2007) (0)
- Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Sw (2018) (0)
- [Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology]. (2001) (0)
- 8029 The expression of CASA in ascites correlates with the overall survival and clinical outcome in patients with ovarian cancer (2009) (0)
- O016/#739 Outcomes of gynaecological cancer surgery during the COVID-19 pandemic: results from the international, multicenter, prospective covidsurg-gynaecological cancer study (2022) (0)
- 8030 Prospective validation of a predictive score for complete tumor resection in recurrent ovarian cancer (ROC): an intergroup study of AGO kommission OVAR, AGO-OVAR, AGO Austria, MITO and NOGGO (2009) (0)
- Application of multiphoton/CARS tomography for detecting early stages of chemotherapeutically induced dermal side effects. (2013) (0)
- Serum C-Reactive Protein as Independent PrognosticVariable in Patients with Ovarian Cancer (2008) (0)
- Interdisciplinary Online Tumorconference: Implementation of a new tool in the management of gynaecological cancers in Germany (2006) (0)
- P32 Why elderly patients have a poorer clinical outcome than younger patients? Results from a large retrospective study on 446 patients (2009) (0)
- 2022-RA-1668-ESGO Patients’perspectives, fears and willingness to take preventive measures during second lockdown of COVID-19 pandemic. A study of NOGGO and EnGAGe Network (2022) (0)
- Tumor-specific correlation of tumor-type M2 pyruvate kinase (Tu M2-PK) in patients with cervical carcinoma. (2006) (0)
- Interim results of the non-interventional C-PATROL study: Real-world treatment data from patients who switched from olaparib capsules to tablets (2020) (0)
- Surgery for Gynecologic Malignancies: Current Trends (2008) (0)
- Impact of malnutrition on surgical outcome of patients with ovarian cancer: Results of a prospective study. (2009) (0)
- Patient care and clinical trials in gynecological oncology: Implications of the COVID-19 pandemic. (2021) (0)
- Adequate utilisation of emergency services in Germany: a differential by migration background? (2019) (0)
- Knowledge and understanding risk factors and preventive measures for osteoporosis in women: results of a survey in 502 women with and without a migration background (2022) (0)
- Pelvine Lymphonodektomie beim Vulvakarzinom – Wohl oder Übel? Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense? (2020) (0)
- BRCA1 methylation status in high-grade serous ovarian cancer (HGSOC) patients (pts). (2012) (0)
- Sentinel lymph node detection in gynecologic malignancies by a handheld fluorescence camera (2017) (0)
- Review of gemcitabine-based combinations for platinum-resistant ovarian cancer (2004) (0)
- AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer (2016) (0)
- HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients (2022) (0)
- 5 years results of a novel simple laparoscopic needle retractor – Ney-Lift (2017) (0)
- Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence (2023) (0)
- 2022-RA-1633-ESGO Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Systematic analysis in 1686 patients (2022) (0)
- Perioperative positioning management in gynecologic cancer surgery: A national NOGGO-AGO intergroup survey. (2017) (0)
- Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study (2022) (0)
- Does the assessment of quality of life (QoL) correlate with clinical response? Results of a prospective study in 374 patients with advanced gynecological malignancies. (2004) (0)
- What do ovarian cancer patients expect from follow-up? Results of a survey of the noggo and ago in 1,015 patients (2008) (0)
- APOBEC 3 B protein expression and mRNA analyses in patients with 1 high-grade serous ovarian carcinoma 2 (2018) (0)
- OC-0564: Randomized trial: Surgical versus clinical staging in cervical cancer patients: Uterus-11-Trial (2020) (0)
- Cytoreductive Surgery in Recurrent Ovarian Cancer. The Desktop Series of the AGO Study Group, Noggo, Mito, AGO-Austria, Sgog and Gineco (2012) (0)
- Somaticcopynumberalterations predictresponsetoplatinumtherapyin epithelial ovarian cancer (2014) (0)
- Abstract B28: Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian cancer. (2016) (0)
- Multimodales Management maligner Ovarialtumore (2005) (0)
- 5. Interdisziplinärer Kongress „Quality of Cancer Care“ (QoCC 2021) (2021) (0)
- 123 Real world data of treatment and outcome of patients with high grade AOC (advanced ovarian cancer) in Germany (QS Ovar) (2021) (0)
- 2022-RA-367-ESGO Rucaparib in clinical practice – what are the elements of patient adherence? (2022) (0)
- Update Onkologie. AGO State of the Art 2015 (2015) (0)
- EP1081 Human papillomavirus genotype and E6 oncoprotein molecular test among cervical cancer patients at Center Mohammed VI for cancer treatment (2019) (0)
- Chronic Pelvic Pain in Endometriosis: Cross-Sectional Associations with Mental Disorders, Sexual Dysfunctions and Childhood Maltreatment (2022) (0)
- An analysis of preoperatively HE4 and CA125 in matched samples of patients (pts) with benign disease and borderline ovarian tumors (BOT) with and without invasive implants (InvImp). (2013) (0)
- Response rate and toxicity of primary concomitant radio-chemotherapy in locally advanced cervical cancer: Results of an open prospective, multicenter phase II study of the NOGGO. (2011) (0)
- Dose-finding study of Topotecan (T) plus Carboplatin (C) for patients with platinum sensitive Relapsed Ovarian Cancer (ROC) (2006) (0)
- 2022-RA-1043-ESGO CT-guided percutenous radiologic gastrostomy in heavily pretreated patients with late stage ovarian cancer: -the charité experiences- (2022) (0)
- Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial (2016) (0)
- The influence of age on treatment and prognosis of patients with squamous cell vulvar cancer (VSCC)- a subset analysis of the AGO-CaRE-1 study (2020) (0)
- 2022-RA-1546-ESGO Potential approach to overcome checkpoint inhibitor resistance in a long-term survivor patient with recurrent endometrial carcinoma (2022) (0)
- Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy (2015) (0)
- 2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy (2022) (0)
- Assessment of high-risk human papillomavirus infections and associated cervical dysplasia in HIV-positive pregnant women in Germany: a prospective cross-sectional two-centre study. (2022) (0)
- Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial (2023) (0)
- Preliminary results of efficacy and tolerability of first-line bevacizumab in combination with carboplatin/paclitaxel in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in clinical practice - a German cohort study. (2015) (0)
- HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients (2022) (0)
- OC-0363: Impact of adjuvant therapy in lymph-node positive vulvar cancer- The AGO-CaRe 1 (Chemo- and Radiotherapy) study (2014) (0)
- 2022-RA-1154-ESGO Ovarian cancer management. Who cares for the Patient? A single case observational study (2022) (0)
- Abstract 5708:HOXA4 and HOXB3gene expression signature as a biomarker of tumor recurrence in patients with high-grade serous ovarian cancer (HGSOC) following primary cytoreductive surgery and first-line adjuvant chemotherapy (2017) (0)
- In vivo changes in the cutaneous antioxidant status during sorafenib, sunitinib and capecitabine treatment. (2017) (0)
- Weekly taxol (T) and carboplatin (P) as first-line therapy in advanced ovarian cancer (AOC) : overall survival data of a phase ii-study in 130 patients(Oncology 1) (2005) (0)
- Long-Term Effects of Neovaginal Reconstruction With Sigmoid Loop Technique on Sexual Function and Self Image in Patients With Gynecologic Malignancies: Results of a Prospective Study (2009) (0)
- Topotecan (T) and carboplatin (C) in the treatment of platinum sensitive relapsed ovarian cancer (ROC): Results of a multicenter phase I/II study. (2006) (0)
- Prediction of intestinal tumor involvement by parameters of nutritional status in patients with primary / recurrent ovarian cancer (2008) (0)
- 8057 How relevant is the CA-125 monitoring for patients with ovarian cancer in the follow-up? – Results from a multicenter survey in 1060 patients with ovarian cancer (2009) (0)
- Peri-operative ovarian cancer guidelines: prehabilitation, enhanced recovery, post-operative ileus prevention, post-operative physiotherapy and mobilization (2022) (0)
- Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens (2023) (0)
- Prognostic value of epithelial cell adhesion molecule (EpCAM) in patients with primary epithelial ovarian cancer. (2012) (0)
- Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial (2012) (0)
- Regional hyperthermia of the abdomen, a pilot study towards the treatment of peritoneal carcinomatosis (2015) (0)
- EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum- (2019) (0)
- Health concerns in long-term survivors with ovarian cancer: Results of Expression VI–Carolin meets HANNA–Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCIG survey. (0)
- 2022-RA-1258-ESGO Patient walk to the operating theatre as a new tool for patient empowerment – KORE-INNOVATION: the first prospective clinical trial to assess a perioperative pathway to reduce postoperative complications in ovarian cancer patients (2022) (0)
- EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer (2021) (0)
- Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO (2023) (0)
- Are there any molecular biologic factors which explain the poorer prognosis of elderly patients with advanced ovarian cancer? (2011) (0)
- The Notion of Diagnostic Delay in the Narratives of Ovarian Cancer Patients : A Suggestion (2017) (0)
- Patients’ subjective assessment as a decisive predictor of malignancy in pelvic masses: results of a multicentric, prospective pelvic mass study (2020) (0)
- SECOND CYCLE OF CATUMAXOMAB TREATMENT IN PATIENTS WITH MALIGNANT ASCITES: RESULTS FROM THE SECIMAS STUDY (2012) (0)
- 2022-RA-211-ESGO Expression of the anti-angiogenic VEGF-A splice variant, VEGF-A165b, as predictive biomarker for bevacizumab treatment in advanced ovarian cancer patients (2022) (0)
- Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis (2022) (0)
- Safety of Uncrossmatched ABO-Compatible RBCs in Alloimmunized Patients with Bleeding: Data from Two Decades: Results of a Systematic Analysis in 6,109 Patients (2021) (0)
- 1. Current aspects in the treatment of ovarian cancer(Session 2 Oncology,Meet the Expert) (2009) (0)
- Final analysis of weekly paclitaxel and weekly carboplatin (P) as first-line chemotherapy in 130 patients with advanced ovarian cancer (AOC) (2005) (0)
- Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice (2019) (0)
- Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1) (2023) (0)
- 393 Long-term neurological side effects in long-term survivors with ovarian cancer (2020) (0)
- First results of Expression V Study, a survey by the North-Eastern-German Society of Gynaecological Oncology (NOGGO), assessing the therapy expectations of breast and ovarian cancer patients with different ethnicity in Germany. (2015) (0)
- SCOUT-1: Prospective non-interventional study in patients with BRCA/HRD-tested ovarian cancer (OC) eligible for first-line (1L) platinum-based chemotherapy (NOGGO ov54). (2022) (0)
- “ Elderly patients ” in gynecologic oncology (0)
- How Much Radicality Do We Need In The Surgery Of Ovarian Cancer (2002) (0)
- Treatment of malignant ascites with catumaxomab in clinical practice: Results of an observational trial (2013) (0)
- Sequential therapy with carboplatin (C) followed by paclitaxel (P) as first-line chemotherapy in 105 patients with advanced ovarian cancer (AOC): Results of a multicenter phase II study of the Northeastern German Society of Gynecological Oncology (2007) (0)
- Progress of evidence-based treatment decision support utilizing Molecular Health Guide in patients with gynecological solid tumors over three to six years (2020) (0)
- 2022-RA-576-ESGO Expression VIII – first study of individual perception and level of information of patients with low grade ovarian cancer and borderline tumor of the ovary in 321 patients (2022) (0)
- ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326) (2022) (0)
- Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging. (2021) (0)
- MITO 12 – pathway to diagnosis of ovarian cancer an observational retrospective multicentered study subgroup of the German data – Charité/Vivantes Netzwerk Berlin (2014) (0)
- Fluorescence-guided mapping of sentinel lymph nodes in gynecological malignancies (2017) (0)
- The impact of pain in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients. (2018) (0)
- Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64]. (2016) (0)
- Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis (2023) (0)
- Results of the first interim analysis of the CARMA study to investigate efficacy and safety profile of catumaxomab in clinical practice. (2012) (0)
- 4. Long-Term Results of Multivisceral Surgery in Patients with Recurrent Ovarian Cancer(IV. Recent Advances in Gynecological Oncology,International Symposium) (2007) (0)
- 8002 What is the best schedule of Topotecan? – weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer – a randomized, multicenter trial of the North-Eastern German Society of Gynaecological Oncology (TOWER) (2009) (0)
- EP869 Treatment of ovarian cancer in Germany from 2004–2016: results of a nationwide quality assurance program (QS Ovar) (2019) (0)
- 2022-RA-800-ESGO AGO-OVAR 27: window-of-opportunity proof-of-concept, non-randomized, open-label phase ii trial of olaparib given alone or in combination with durvalumab prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (2022) (0)
- Role of estrogen receptor-related receptors α, β and γ in ovarian cancer cells (2005) (0)
- Safety of erythropoetin administration in first-line chemotherapy of ovarian carcinoma: Results of a prospective study (2008) (0)
- Epidermal growth factor receptor (EGFR) mutation incidence in Caucasian ovarian cancer patients (2006) (0)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer (2021) (0)
- Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. (2023) (0)
- Lipid reprogramming induced by the TFEB-ERRα axis enhanced membrane fluidity to promote EC progression (2022) (0)
- Evaluation of homeobox (HOX) gene expression as a prognostic biomarker of time to recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients treated with adjuvant carboplatin plus paclitaxel (A-C/P). (2016) (0)
- TP017/#1455 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204) (2022) (0)
- 358 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3 (2020) (0)
- EP809 Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: an analysis of five prospective phase II/III trials of NOGGO metadata base (2019) (0)
- Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature (2023) (0)
- 8059 Multicenter survey of 323 gynaecological departments in Germany: current standards in the clinical management of borderline tumours of the ovary (2009) (0)
- Does the assessment of quality of life (QoL) correlate with clinical response? Results of a prospective study in 374 patients with advanced gynecological malignancies (2004) (0)
- ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer. (2022) (0)
- Discriminatory protein profiles in ovarian cancer tissue of platinuù resistant vs sensitive patients, a prospective OVCAD study (2009) (0)
- EP264/#556 Physician-reported patient involvement in 1l ovarian cancer treatment, including maintenance, in the US and Europe: a real-world chart review analysis (2017–2020) (2022) (0)
- 2022-RA-1548-ESGO Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer (2022) (0)
- Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer (2022) (0)
- Prediction of nutritional status and intestinal tumor involvement in patients with primary or recurrent ovarian cancer: Results of a prospective study. (2009) (0)
- Expression of the ELAV-like protein HuR in ovarian carcinoma (2004) (0)
- 2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer (2022) (0)
- INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2023) (0)
- What is the prognostic role of bone metastases in ovarian cancer: Results of an analysis of 1,717 patients. (2011) (0)
- Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial. (2021) (0)
- Ichthyosis uteri (Psoriasis uteri) (2018) (0)
- TP038/#1408 Rucaparib maintenance after bevacizumab maintenance following carboplatin based first line chemotherapy in ovarian cancer (2022) (0)
- How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC). (2019) (0)
- 0263: Over-Expression of Estrogen Receptor-Related Receptor Alpha 1 May Provide a Resistant Mechanism of Endocrine Therapy in Ovarian Cancer Cells (2006) (0)
- Participation of elderly gynecological cancer patients in clinical trials. (2017) (0)
- IS-27 A New Therapeutical Approach : Topotecan Plus Gemcitabine In The Treatment Of Patients With Relapsed Ovarian Cancer (2002) (0)
- Changes of serum glycome in patients suffering from ovarian cancer. (2012) (0)
- Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an anti-angiogenic VEGF-A splice variant. (2022) (0)
- A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany (2023) (0)
- A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy. (2022) (0)
- Peri-operative ovarian cancer guidelines: psycho-oncology (2022) (0)
- Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer (2018) (0)
- 348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO) (2020) (0)
- Peritoneal and upper genital tract tuberculosis mimicking an advanced fallopian tube carcinoma: A case report and a systematic literature review (2018) (0)
- Acknowledgement to Reviewers (2007) (0)
- GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis (2018) (0)
- Olaparib routine clinical practice in Germany – Quality of life interim results of the non-interventional C-PATROL study (2020) (0)
- 2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer (2022) (0)
- Topotecan (T) + Pazopanib (P) in platinum-resistant or intermediate-sensitive ovarian cancer: a phase I/II single-arm multicentre trial of the North-Eastern German Society of Gynaecologic Oncology: TOPAZ. (2018) (0)
- 2022-RA-837-ESGO Characterization of long-term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO/A-AGO (2022) (0)
- Prognostic factors in ovarian cancer patients with brain metastases: Results of a German multicenter study. (2016) (0)
- Abstract 5702: Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study (2023) (0)
- Primary Treatment Results in Patients with Ovarian, Fallopian or Peritoneal Cancer—Results of a Clinical Cancer Registry Database Analysis in Germany (2022) (0)
- Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. (2022) (0)
- First Evaluation of the Joint Clinical Registry Data of Patients with Primary Ovarian Cancer at the Coordinating Tumor Center of Berlin (2011) (0)
- LION-PAW – Lymphonodectomy (LNE) in Ovarian Neoplasm – Pleasure Ability of Women Prospektive Substudie der multizentrischen AGO LION Studie (2018) (0)
- Lymphadenectomy in Advanced Ovarian Neoplasms. Reply. (2019) (0)
- 2022-RA-1391-ESGO Perioperative non-invasive advanced hemodynamic monitoring of patients with primary ovarian cancer undergoing multivisceral debulking surgery (2022) (0)
- 2022-RA-1094-ESGO Implementation of a tri-modal prehabilitation intervention – KORE-INNOVATION: the first prospective clinical trial to assess a perioperative pathway to reduce postoperative complications in ovarian cancer patients (2022) (0)
- Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer (2022) (0)
- TP025/#1399 Artistry-7: phase 3 multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (2022) (0)
- Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory to clinic (2009) (0)
- The role of clinical and surgical factors characterizing longterm-survival in ovarian cancer. (2016) (0)
- 2022-RA-1725-ESGO Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer- results of a multicentre NOGGO phase I and II study (TOPAZ) (2022) (0)
- Sentinel Lymph Node Staging with Indocyanine Green for Patients with Cervical Cancer: The Safety and Feasibility of Open Approach Using SPY-PHI Technique (2021) (0)
- Effects of polymorphism (plm) in interleukin (IL) 1 and IL10 genes on surgery outcome in ovarian cancer (OC). (2006) (0)
- Prospective, multicenter study on non-pharmacological, patient related predictive factors of chemotherapy induced nausea and vomiting (CINV): A NOGGO-EMRISK trial. (2022) (0)
- Prevention of hand foot syndrome using an antioxidant containing ointment in patients treated with pegylated liposomal doxorubicin a randomized placebo controlled double-blind study. (2015) (0)
- A combined Blood-based Gene-Expressions and Plasma-Signature for the Diagnosis of epithelial Ovarian Carcinoma - A Study by the OVCAD Consortium (2012) (0)
- Cervical Cancer and -463G/A Polymorphism of MPO Gene (2006) (0)
- Can intraperitoneal chemotherapy be regarded as a new standard in advanced ovarian cancer (2006) (0)
- P142 Results of the 3rd interim analysis of C-Patrol: a non-interventional study on olaparib in german routine clinical practice (2019) (0)
- Recurrent ovarian cancer and management of elderly patients: Results of a prospective trial of treosulfan focusing on patient's preference and clinical outcome (NOGGO-Preference-Study). (2012) (0)
- Impact of COVID-19 on gynaecological patient care: results of patient’s survey with 327 patients (2021) (0)
- Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. (2023) (0)
- P51 Nutritional status and clinical outcome of elderly women with primary or recurrent ovarian cancer: results of a prospective study (2009) (0)
- Analysis of heat shock protein HSP27 secretion in an ovarian cancer cell model and detection of cell-free HSP27 in patient blood serum sample. (2015) (0)
- Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer (2011) (0)
- 164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (0)
- 8007 ORAL Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment (2011) (0)
- Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study). (2018) (0)
- Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial. (2012) (0)
- Frailty Index for Prediction of Surgical Outcome in Ovarian Cancer: Results of a Prospective Study (2021) (0)
- Information needs and preferences of women with adjuvant and metastatic breast cancer (BC): Results of a survey in Germany (2005) (0)
- First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology. (2011) (0)
- EP1168 The influence of obesity on tumor recurrence in vulvar cancer patients (2019) (0)
- Incidence patterns and survival of gynecological sarcoma in Germany: Analysis of population-based cancer registry data on 2106 women, 2009-2013. (2017) (0)
- Frailty score: Prediction of postoperative morbidity and mortality in surgical oncology? (2016) (0)
- MDM 2 SNP 309 modifies the prognostic significance of the p 53 mutational status in patients with ovarian cancer (2011) (0)
- Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab. (2014) (0)
- The role of HE4 in predicting surgical outcome in recurrent ovarian cancer (ROC). (2011) (0)
- 2022-LBA-607-ESGO How long do our patients stay fasting? a multicentric prospective survey on the perioperative fasting in 924 Patients conducted by the JAGO study group (2022) (0)
- What do adjuvant and metastatic cancer patients expect from their treatment, palliative care, and physicians? Results of a German survey on 607 patients. (2014) (0)
- Real-World Evidence: How Long Do Our Patients Fast?—Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases (2023) (0)
- 2022-RA-1467-ESGO Digital health-related app support of patients with gynaecological malignancies: results of a pilot study (2022) (0)
- Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II). (2022) (0)
- 155 Prognostic value and therapeutic implications of pleural carcinosis and malignant pleural effusion in advanced epithelial ovarian cancer (2020) (0)
- ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) C (2022) (0)
- Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ). (2023) (0)
- The-463 G / A Polymorphism in Myeloperoxidase Gene and Cervical Cancer (2008) (0)
- Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation (2019) (0)
- 2022-RA-1083-ESGO FraStROC —frailty stratification for recurrent ovarian cancer development and prospective validation of a frailty score for chemotherapy associated toxicity in relapsed ovarian cancer (2022) (0)
- 2022-RA-1347-ESGO The impact of the induction of anaesthesia and the opening of the abdominal cavity on haemodynamic parameters in cytoreductive debulking surgery (2022) (0)
- A comparative randomized, placebo-controlled, double-blind phase II study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment for advanced ovarian cancer. (2011) (0)
- Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group (2023) (0)
- Surgical outcome score (SOS), a new algorithm based on HE4 and CA125, to predict surgical outcome in primary epithelial ovarian cancer (EOC) patients (pts). (2013) (0)
- Relevance of estrogen activating STS and inactivating SULT1E1 enzymes and estrogen receptors [alpha/beta] in patients with advanced ovarian cancer (2014) (0)
- EXPRESSION PATTERN OF HUMAN ESTROGEN RECEPTOR- RELATED RECEPTOR – ALFA-BETA, A SUB- FAMILY OF ORPHAN NUCLEAR RECEPTORS, AND THE ESTROGEN RECEPTOR ON HUMAN OVARIAN CANCER CELL LINES (2004) (0)
- 00096 PRE-OPERATIVE SELECTION CRITERIA FOR OPERABILITY IN RECURRENT OVARIAN CANCER (DESKTOP-OVAR) (2005) (0)
- Ovarian tumors of different histologic type and clinical stage induce similar changes 1 in lipid metabolism 2 Running title : Various ovarian tumors affect blood lipidome 3 4 (2018) (0)
- Abstract 4723: Soluble L1-CAM in the ascites is a prognostic marker in ovarian cancer (2011) (0)
- Patients’ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life—a study of the North-Eastern-German Society of Gynecological Oncology (2019) (0)
- Characterisation of Microscopic Changes in Macroscopically Unaffected Peritoneum in Women with and without Endometriosis (2021) (0)
- Influence of IL-1 RA expression in ascites on overall survival (OS) of advanced ovarian cancer (OC) patients (pts) (2005) (0)
- 2022-RA-991-ESGO Assessment of high-risk human papillomavirus infections and cervical dysplasia in human immunodeficiency virus-positive pregnant women in germany: a prospective cross-sectional two-center study (2022) (0)
- 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer (2021) (0)
- Abstract AP15: IDENTIFICATION OF P53 PRIONS AS AN INDEPENDENT PROGNOSTIC MARKER FOR SURVIVAL IN HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
- 2022-RA-1460-ESGO Potentials and challenges of individualized aromatherapy for women with gynecological cancers in aftercare –It’s like one part of the puzzle: Results from an explorative pilot study (2022) (0)
- Current clinical trials in ovarian cancer (2011) (0)
- P50 Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival (2009) (0)
- A Promising Approach for Primary Cytoreductive Surgery for Advanced Ovarian Cancer: Survival Outcomes and Step-by-Step Description of Total Retroperitoneal en-Bloc Resection of Multivisceral-Peritoneal Packet (TROMP) (2022) (0)
- Correction to: Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study (2021) (0)
- 2022-RA-420-ESGO Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC) – real world data of the german quality assurance project (QS Ovar of the AGO Study Group) (2022) (0)
- 560 Analysis of 168 primary adult ovarian granulosa cell tumors, its clinicopathological outcome, and risk factors for recurrence (2021) (0)
- 2022-RA-285-ESGO Real world data of treatment and outcome of patients with early ovarian cancer (FIGO I) in Germany (QS Ovar of the AGO Study Group) (2022) (0)
- Effects of cancer therapy on sexuality and quality of life (QoL) of patients with gynecologic malignancies (GM): Results from 55 pts. (2012) (0)
- 463 LVSI and Ki67 in prediction of lymph-node metastasis in primary low-grade ovarian cancer (2020) (0)
- Analysis and validation of differential gene expression in serous ovarian tumors of varying grade and malignant potential (2005) (0)
- 825P Olaparib maintenance therapy in routine clinical practice: Quality of life interim results of the non-interventional C-PATROL study in ovarian cancer patients in Germany (2020) (0)
- 000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) (2005) (0)
- Pretreatment with methanolic extract of Pistacia lentiscus L. increases sensitivity to DNA damaging drugs in primary high-grade serous ovarian cancer cells (2020) (0)
- Erratum to "GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee" [Cancer Treatm. Rev. 107 (2022) 102396]. (2022) (0)
- Influence of appropriate emergency department utilization and verbal communication on physicians’ (dis)satisfaction with doctor–patient interactions with special consideration of migrational backgrounds (2022) (0)
- Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. (2022) (0)
- Methylation reversal reveals Snk/PLK2 as a critical determinant of clinical outcome in ovarian cancer (2008) (0)
- 1061 Clinical impact of mesothelin expression in ovarian cancer: a tissue microarray study on 113 Patients (2021) (0)
- Thema : p 53 codon 72 polymorphism in HPV-related cervical cancer (2010) (0)
- 2022-RA-647-ESGO Real-word therapy and clinical and patient-reported outcomes in patients with newly diagnosed advanced ovarian cancer: first description of the SCOUT-1 study centers (NOGGO ov54, NCT04830709) (2022) (0)
- Effect of catumaxomab on EpCAM+ tumor cells in vitro in the presence of immune effector cells from ovarian cancer patients treated with chemotherapy. (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jalid Sehouli?
Jalid Sehouli is affiliated with the following schools:
